Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope so-eom
Rocky/Rumit- I thought that I raed in a presentation a while ago that in the mice studies some of the photo receptors that were -for lack of a better term "borderline" --became rejuvenated/active and thus improved vision by some factor...maybe it is just what I want to believe as opposed to reality. Thank you in advance for keeping me in the REAL WORLD.
some opinions are best left ignored-jmho
two weeks!!thank u-eom
Thanks Rocky/Rumit IMHO-they are waiting for the official written/signed/sealed delivered notification--although i would be happy with a pr in the morning--glta
My guess-injection tues 6/28-early morning--just a guess for FUN. no facts/info behind it
thank you rumit-eom
thank you elysse-glta-eom
agreed-
It is the ongoing posting of wrong info and statements that are not or can not be backed up with facts that annoy me. I have my own "pie in the sky" and negative thoughts at times and appreciate that others will have a different opinion, especially when they confront me with facts/numbers. I look forward to reading more of your posts diannedawn--positive or negative or just insightful--glta
I have written to mgt to no avail-perhaps if others sent a brief note as well they might listen
good night
I ignore some people-its easy!!EOM
Rocky has always offered us analysis, research, facts and I do not recall a pps forecast, assumptions or a statement that he could not back-up with numbers/a quote/financial statement/ACTC slide...he has kept me firmly grounded in a consistent realty. Rocky has given me facts when I had "visions of sugar plums" and when I had a negative view of things that were only in my imagination. Just my two cents--fwiw
Rocky/all you good folks-thank you!!eom
Happy Fathers to you!!!
I have heard some reasons in the past: manipulation, delays, lawsuits, no appointed CEO, dilution, too many O/Ss, reverse split, no JV, No news,...Dr Lanza sneezed. imho--it is just the nature of this beast/ride we are on---some moments make you sick to your stomach---others are exciting. If you are a long--just hang on and try to enjoy the ride--glta riders
first patient will be treat by end of second Q
approx the next 24 hours?? WOW
Ford good luck with your purchases--GLTA-eom
Spetty- I agree with your post and am on your side. Some folks are not really fans of ACTC. I am long and waiting--glta longs (although i do not have a problem with shorts)
Thank you-eom
Farview--all the best to you. there many waiting for stemcell help for a variety of reasons. I am one of those as well. My sincerest best wishes that things work out well for you in the very near future!!! I hope you make money with actc---more important--I hope that you have the opportunity to enjoy spending it!!!
great response to biowork's comments----you keep us/ME grounded in reality with the facts. thank you, good night and good luck to you.
I was thinking a large pharma would want to jv--invest in the further clinical development--with the idea of a long term product/marketing venture if the results after several US patients and global patients showed positive results (probably in the fall). kind of like the Korean deal only with more favorable terms. Thank you in advance.
What about the impact of a potential JV after positive phase 1/11 results in the next few months, especially if we get efficacy and not just safety? I know that I am swinging for the fences but wondered what those a little/lot more savvy than I think? Your thoughts are appreciated--thank you
Interstate--thank you!!!
IMHO-- Institutions would not be jumping into this stock at the moment whatever the price. Some reasons why: lack of understanding in regard to the science, interim ceo, misperception about destroying embryos, trials that have been postponed many times, many similar companies making GREAT claims (many later proven wrong), history of virtual bankruptcy, etc etc... I believe that Rabin/mgt and Terren P will do what is best to protect our/their interest---a high mkt cap and pps in due time. I offer no advice as I have made a BUNCH of BAD financial decisions in the past---but I am long and holding on. GLTA
hoping .35 is only the beginning for all of us--eom
THANK YOU__EOM
good luck and I hope actc is the your seven bagger plus a few extra bags--thank you for your story
Is court ruling final? or does the appeals process continue---please tell ne me this decision is final!!! thank you in advance
Just hoping for the best now-glta
ACT Announces UCLA Institutional Review Board (IRB) Approval of its Phase 1/2 Clinical Trials using hESC-Derived RPE Cells for the Treatment of Macular Degeneration - Yahoo! Finance
MARLBOROUGH, Mass., April 28, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) has received institutional review board (IRB) approval to be a site for its Phase 1/2 human clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
"It is only appropriate that an institution with the global stature of UCLA's Jules Stein Eye Institute would be a site for the first-ever clinical trials using embryonic-derived stem cells to treat diseases of the eye, and we could not be more pleased," said Gary Rabin, interim chairman and CEO of ACT. "One of the world's foremost institutions for ophthalmology-related clinical trials, the institute represents an ideal partner for both trials, and we are eagerly anticipating starting them as soon as possible."
The Phase 1/2 trials will be prospective, open-label studies designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation into patients with SMD and Dry AMD.
"The outstanding scientific and leadership teams at ACT are extremely impressive. Together, our collaboration has led to both FDA and IRB permission to commence these trials. This signals the long-awaited societal and institutional 'green light' to take what will hopefully be a huge step forward into the realm of human stem cell science. I am honored to be leading the clinical collaboration," said Steven Schwartz, MD, Ahmanson Professor and Retina Division Chief, at UCLA's Jules Stein Eye Institute and Principal Investigator of the trials.
Enrollment criteria for patient selection will be posted at Home - ClinicalTrials.gov in coming days.
About Dry AMD and SMD
Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. As many as thirty million people in the United States and Europe suffer from macular degeneration, which represents a $25-30 billion worldwide market that has yet to be effectively addressed.
Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority the "dry" form of AMD – which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.
Stargardt's Macular Dystrophy (SMD) is one of the most common forms of macular degeneration in the world. SMD causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit Advanced Cell Technology.
About the Jules Stein Eye Institute
Established in 1966, the Jules Stein Eye Institute represents the culmination of a dream shared by ophthalmologist, businessman and philanthropist Dr. Jules Stein and his wife Doris, of creating a world-renowned center dedicated to the preservation of vision and the prevention of blindness. The Institute's comprehensive programs for the care of patients with eye disorders, research in the vision sciences, education in the field of ophthalmology and outreach to the community, coupled with its state-of-the art facilities, have brought national and international recognition to the Institute and UCLA. Many have contributed to this tradition of excellence and many more will carry it forward as the Institute continues its mission to advance ophthalmology worldwide.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful
HAPPY EASTER
Inter--Thank you!!--eom
she is just looking for hits/responses to make a few bucks --if she causes an investor to loose money--she does not care.........strategy used by many is totally ignore her and not respond or post---
what is special about april 8th--thanks
A-Taco--well put....the ongoing speculation is draining and yes a waste of time----I say this in particular for the newbies--glta
Please note that the article ends with them still having issues to resolve!!!I believe these are the same issues that other scientists have encountered and Lanza has avoided.